CO2022009561A2 - Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4 - Google Patents

Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4

Info

Publication number
CO2022009561A2
CO2022009561A2 CONC2022/0009561A CO2022009561A CO2022009561A2 CO 2022009561 A2 CO2022009561 A2 CO 2022009561A2 CO 2022009561 A CO2022009561 A CO 2022009561A CO 2022009561 A2 CO2022009561 A2 CO 2022009561A2
Authority
CO
Colombia
Prior art keywords
melanocortin
treatment methods
disorders associated
receptor pathway
receptor
Prior art date
Application number
CONC2022/0009561A
Other languages
English (en)
Spanish (es)
Inventor
Der Ploeg Leonardus H T Van
Alastair Garfield
Bhavik P Shah
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of CO2022009561A2 publication Critical patent/CO2022009561A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CONC2022/0009561A 2020-09-24 2022-07-07 Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4 CO2022009561A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063082867P 2020-09-24 2020-09-24
PCT/US2021/052032 WO2022067086A1 (en) 2020-09-24 2021-09-24 Methods of treating melanocortin-4 receptor pathway-associated disorders

Publications (1)

Publication Number Publication Date
CO2022009561A2 true CO2022009561A2 (es) 2022-07-19

Family

ID=80845850

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0009561A CO2022009561A2 (es) 2020-09-24 2022-07-07 Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4

Country Status (13)

Country Link
US (1) US20240058414A1 (https=)
EP (1) EP4216979A4 (https=)
JP (1) JP2023542985A (https=)
KR (1) KR20230095956A (https=)
CN (1) CN116507353A (https=)
AR (1) AR123603A1 (https=)
AU (1) AU2021350017A1 (https=)
CA (1) CA3192873A1 (https=)
CL (1) CL2023000823A1 (https=)
CO (1) CO2022009561A2 (https=)
MX (1) MX2023003360A (https=)
TW (1) TW202228760A (https=)
WO (1) WO2022067086A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023308310A1 (en) * 2022-07-12 2025-01-16 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
EP4618952A2 (en) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
WO2025106751A1 (en) * 2023-11-14 2025-05-22 Rhythm Pharmaceuticals, Inc. Combinations of a potassium channel activator and an mc4r agonist and related methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2286825T3 (pl) * 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4

Also Published As

Publication number Publication date
CL2023000823A1 (es) 2023-09-15
AU2021350017A1 (en) 2023-05-04
JP2023542985A (ja) 2023-10-12
AU2021350017A9 (en) 2024-10-03
MX2023003360A (es) 2023-06-23
US20240058414A1 (en) 2024-02-22
EP4216979A1 (en) 2023-08-02
WO2022067086A1 (en) 2022-03-31
CN116507353A (zh) 2023-07-28
EP4216979A4 (en) 2024-11-06
AR123603A1 (es) 2022-12-21
CA3192873A1 (en) 2022-03-31
KR20230095956A (ko) 2023-06-29
TW202228760A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
CO2022009561A2 (es) Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4
CL2022001256A1 (es) Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt
CO2021008998A2 (es) Amidas de pirrolidina iii sustituidas
CO2021005231A2 (es) Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha)
CR20210592A (es) Moduladores de la vía integrada del estrés
EA201992474A3 (ru) Агонисты 5ht для лечения нарушений
CL2016002998A1 (es) Aparatos de tratamiento de líquido electroquímico
MX382216B (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CO2020005417A2 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
MX2016013863A (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos.
PH12017502120A1 (en) A method and an apparatus for forming a lignin fraction, a lignin composition and its use
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
EP4360704A3 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
CL2025000071A1 (es) Métodos para tratar la obesidad con un agonista de mc4r
UY32449A (es) Benzazepinas fusionadas como ligandos de receptor de acetilcolina nicotínico neuronal
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
MX388890B (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
CR20180583A (es) Anticuerpos antifactor de la coagulación xi
CL2023003126A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
EA201891253A1 (ru) Способ получения высококачественного исходного материала для процесса парового крекинга
MX2022007368A (es) Composiciones y metodos de tratamiento del cancer con receptores de antigenos quimericos dirigidos al glipicano 3.
CL2025002297A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa.
MX2020001867A (es) Sistemas y metodos para mejorar la meditacion.
AR100734A1 (es) Método para tratar leucemia linfocítica crónica (cll)